Advertisement
Advertisement
U.S. markets close in 5 hours
Advertisement
Advertisement
Advertisement
Advertisement

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.03000.0000 (0.00%)
As of 03:00PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0300
Open0.0275
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0300 - 0.0300
52 Week Range0.0216 - 0.2203
Volume386,009
Avg. Volume100,951
Market Cap11.053M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.0840
Earnings DateJul 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • TETRA BIO PHARMA INC
    Analyst Report: Microsoft CorporationMicrosoft is the world's largest independent software developer. The company was founded on the MS Windows operating system and MS Office business applications suite for PCs. As it has grown, Microsoft has expanded into enterprise software with Windows Server, SQL Server, Dynamics CRM, SharePoint, Azure, and Lync; hardware with the Xbox gaming/media platform and the Surface tablet; and online services through MSN and Bing. Microsoft acquired Skype, the internet VoIP communications service, in October 2011. More than 50% of revenue is generated outside the U.S.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • CNW Group

    Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the "Financing") with Global Corporate Finance Opportunities 16 (the "Investor"), an investment vehicle advised by Alpha Blue Ocean ("ABO"), and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the term

  • CNW Group

    IIROC Trade Resumption - TBP

    Trading resumes in:

  • PR Newswire

    Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.

Advertisement
Advertisement